Sorafenib is a drug used to treat hepatocellular carcinoma (primary liver cancer). However, in many patients the cancer eventually continues to grow. Stereotactic body radiation therapy (SBRT) is another treatment for liver cancer. It involves the use of focused high-dose radiation generally delivered to the liver in five or fewer sessions.
In this study, researchers want to see if using both therapies together is more effective than sorafenib alone (the current standard of care) for treating inoperable liver cancer. Patients will be randomly assigned to receive sorafenib alone (a tablet which is taken by mouth) or SBRT followed by sorafenib.